SEVERANCE AND CHANGE IN CONTROL AGREEMENTSeverance and Change in Control Agreement • March 14th, 2019 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
THIS SEVERANCE AND CHANGE IN CONTROL AGREEMENT (the “Agreement”), made this 13th day of March 2019 (the “Effective Date”), is entered into by AVEO Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 1 Broadway 14th Floor, Cambridge, MA 02142 (the “Company”), and Karuna Rubin (the “Employee”).
AGREEMENTAgreement • March 14th, 2019 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
Agreement (the “Agreement”), dated December 18, 2018 (the “Agreement Effective Date”), by and between Novartis International Pharmaceutical Ltd. (“Novartis”) and AVEO Pharmaceuticals, Inc. (“AVEO”). Novartis and AVEO are separately referred to as a “Party” and are collectively referred to as the “Parties”.
